Yuhan

유한양행 · 000100

Health Care Pharmaceuticals · KOSPI

Large-cap

Market cap US$4.7B (₩6.5T)

Overview

Yuhan makes prescription and over-the-counter medicines, drugs used to treat everyday and chronic conditions, as well as other health-care products supplied to patients and healthcare providers in Korea.

The company is listed on KOSPI, Korea's main stock exchange. The filing covers a broad range of business activities including product development, raw-material sourcing, and active research and development, suggesting a diversified pharmaceutical operation rather than reliance on a single product line.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$1.6B

▲ +5.8% YoY

Operating profit · FY2025

US$75.6M

▲ +90.2% YoY

Net income · FY2025

US$134.3M

▲ +235.9% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$1.3B(₩1.9T)	US$1.5B(₩2.1T)	US$1.6B(₩2.2T)
Operating profit	US$41.1M(₩56.8B)	US$39.8M(₩54.9B)	US$75.6M(₩104.4B)
Net income	US$97.1M(₩134B)	US$40M(₩55.2B)	US$134.3M(₩185.3B)

Revenue

FY2023US$1.3B
FY2024US$1.5B
FY2025US$1.6B

Operating profit

FY2023US$41.1M
FY2024US$39.8M
FY2025US$75.6M

Net income

FY2023US$97.1M
FY2024US$40M
FY2025US$134.3M

Key ratios (FY2025)

ROE

7.8%

Debt/Eq

36.4%

Op. margin

4.8%

Net margin

8.5%

Rev. YoY

▲ +5.8%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?